SCHEMBL2176128

SCHEMBL2176128

COc1cc2nccc(Oc3ccc(CC(=O)Nc4nc(C)cs4)cc3)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.64
KDR P35968 4/20 0.63
CSF1R P07333 3/20 0.63
PDGFRB P09619 3/20 0.63
FLT3 P36888 2/20 0.63
KDM4E B2RXH2 1/20 0.63
LMNA P02545 1/20 0.63
TSHR P16473 1/20 0.63
MAPK1 P28482 1/20 0.63
MAPK10 P53779 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
FLT4 P35916 1/20 0.60
PDGFRA P16234 6/20 0.57
KIT P10721 3/20 0.57
RET P07949 1/20 0.56
DDR1 Q08345 1/20 0.56
RAB9A P51151 2/20 0.54
ALDH1A1 P00352 1/20 0.54
WNT3A P56704 1/20 0.54
AXL P30530 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175586 0.92 MET (0.57) METKDRCSF1RPDGFRBFLT3
SCHEMBL2173153 0.92 SMN1; SMN2 (0.55) METKDRCSF1RPDGFRBFLT3
SCHEMBL5610715 0.89 SMN1; SMN2 (0.55) METKDRCSF1RPDGFRBFLT3
SCHEMBL1097598 0.86 PDGFRB (0.65) KDRCSF1RPDGFRBFLT3KDM4E
SCHEMBL1099584 0.81 PDGFRB (0.59) KDRCSF1RPDGFRBFLT3KDM4E
SCHEMBL1099359 0.81 PDGFRB (0.59) KDRCSF1RPDGFRBFLT3KDM4E
SCHEMBL2173476 0.81 PDGFRB (0.67) METKDRCSF1RPDGFRBFLT3
SCHEMBL2174404 0.81 KDR (0.51) METKDRCSF1RPDGFRBFLT3
SCHEMBL2172313 0.81 PDGFRB (0.57) METKDRCSF1RPDGFRBFLT3
SCHEMBL13587173 0.80 MET (0.89) METKDRCSF1RPDGFRBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 MET 3334/4885KDR 2277/4885CSF1R 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.